Looking for more editions of Flow Matters? View Library
Last Updated: 23 November 2020 (NZDT)
At the beginning of the pandemic, a low threshold for early intubation and mechanical ventilation was recommended to protect HCWs. NHF has emerged as a mode of respiratory support favored for its role in reducing the need for tracheal intubation. Initial concerns over NHF are being reconsidered in light of the requirement for NHF as a mode of respiratory support.1
Use of NHF features in guidelines for the clinical management of COVID-19 from the World Health Organization (WHO)7, the National Institutes of Health (NIH)8, the European Society of Intensive Care Medicine (ESICM)*, the Society of Critical Care Medicine (SCCM)*9 and the Australia and New Zealand Intensive Care Society (ANZICS)10.
Table 1. Guideline recommendations for use of NHF on COVID-19 patients.
As NHF has been adopted for use in COVID-19, observational research on its clinical application has been peer reviewed and published.
Table 2. Healthcare worker outcomes in use of NHF on COVID-19 patients.
The potential risk posed to HCWs by infectious patients has heightened research interest in the dispersion of exhaled particles which may increase risk of nosocomial infection.
Table 3. Particle dispersion from use of NHF on COVID-19 patients.
In addition to the data from publications on dispersion in Table 3, Hui et al. 2019 and Hui et al. 2014 compared a range of respiratory therapies and interfaces with a method for evaluating the dispersion of exhaled air using smoke and lasers to trace air movement from a human patient simulator. Collated air dispersion results from the two studies conducted by Hui et al.17,18 are illustrated in the chart below.
¶ Dispersion distance data shown on the chart is combined from two studies conducted by the same authors.
The experiments were conducted in rooms with different configurations. Not all of the interfaces depicted were directly compared.
How to operate the AIRVO 2, including guidance on how to adjust key settings such as flow, temperature, and how to add supplemental oxygen (if required).
Flow Matters | Edition 10
Updated: 23 November 2020 (NZDT)
COVID-19 Useful Links Document
Published: 12 June 2020, 2:11PM (NZDT)
AIRVO 2 and COVID-19
Updated: 24 March 2020, 4:27PM (NZDT)
Delivering respiratory support for spontaneously breathing patients
Full face masks designed for comfort and care
Providing Optimal Humidity for intubated patients
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
Nasal High Flow and Humidification for patients at home and in long term care
Home respiratory therapies that deliver humidification via a mask or tracheotomy tube to support and complement the airway’s natural-defense mechanisms
A flow range of 2 to 60 L/min allows for use across the care continuum - from the most acute hospital environment to the home
With Optiflow you can independently titrate flow and FiO2 according to your patient's needs
F&P Evora™ incorporates CapFit headgear that has been designed to be put on like a cap
The adaptable, reliable and robust humidification system. Use with Evaqua™ 2 circuit technology to minimize condensate
Updates and support for healthcare professionals
Stories, news and media resources
Looking after our people, suppliers, communities and the environment
Featuring stories and ideas in healthcare and technology that capture our imagination